 Participants: Participants will be 120 lymphoma survivors diagnosed with either non-Hodgkins lymphoma NHL or Hodgkins disease HD and receiving or not receiving at least 8 weeks of chemotherapy at the Cross Cancer Institute in Edmonton, Alberta. Participants will be stratified by disease type indolent NHL versus aggressive NHL versus HD and planned chemotherapy protocol no chemotherapy versus 16 weeks versus 16 weeks, and randomly assigned to either a 12 week exercise program or usual care. 